{"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"47"},{"groupId":"BG003","value":"112"}],"units":"Participants"}],"groups":[{"description":"All participants from Phase I","id":"BG000","title":"Phase I All Participants"},{"description":"Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.\n\nCediranib Maleate: Given orally\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPemetrexed Disodium: Given IV","id":"BG001","title":"Phase II Cisplatin-pemetrexed Cediranib 20mg"},{"description":"Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.\n\nPlacebo: Given orally\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPemetrexed Disodium: Given IV","id":"BG002","title":"Phase II Cisplatin-pemetrexed Placebo"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"43.6","upperLimit":"83.6","value":"64.4"},{"groupId":"BG001","lowerLimit":"45.5","upperLimit":"82.1","value":"71.3"},{"groupId":"BG002","lowerLimit":"50.9","upperLimit":"85.3","value":"71.8"},{"groupId":"BG003","lowerLimit":"43.6","upperLimit":"85.3","value":"69.8"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"93"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"104"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"100"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"105"}],"title":"0-1"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"}],"title":"2"}]}],"description":"Patients will be graded according to the Zubrod Performance Status Scale:\n\n0: Fully active, able to carry on all pre-disease performance without restriction.\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.\n2. Ambulatory and capable of self-care but unable to carry out any work activities; up and about more than 50% of waking hours.\n\nThe higher grade is, the worse performance status is.","paramType":"COUNT_OF_PARTICIPANTS","title":"Zubrod Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"87"}],"title":"Epitheliod or mesothelioma, NOS"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"25"}],"title":"Biphasic or sarcomatoid"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"22"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"90"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior history of radiation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"21"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"91"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior history of definitive surgery","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"92"}],"title":"Measurable"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"20"}],"title":"Non-measurable"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Measurable Disease per RECIST 1.1","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"85"}],"title":"Measurable"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"27"}],"title":"Non-measurable"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Measurable Disease per Modified RECIST for Pleural Tumors","unitOfMeasure":"Participants"}],"populationDescription":"117 participants were enrolled, only 112 participants were included in the analysis: 5 patients were either not eligible or not analyzable. Thus these 5 patients were excluded from any analysis."}